RCT | Tixagevimab-cilgavimab for treatment of patients hospitalized with COVID-19.

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial – The Lancet Respiratory Medicine

Commentary: The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients – News Medical

Related:

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial – The Lancet Respiratory Medicine

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 – New England Journal of Medicine

Commentary on Twitter

In pts hospitalised w/ COVID-19 receiving remdesivir and other standard care, tixagevimab–cilgavimab did not improve time to sustained recovery but was safe and mortality was lower vs placebo

From the ACTIV-3–TICO Study Group https://t.co/zaaXBQYl5t pic.twitter.com/xe0tmbFrZ9

— The Lancet Respiratory Medicine (@LancetRespirMed) July 11, 2022